WO2022213975 - COMPOUNDS TARGETING Y220C MUTANT OF P53
National phase entry is expected:
Publication Number
WO/2022/213975
Publication Date
13.10.2022
International Application No.
PCT/CN2022/085296
International Filing Date
06.04.2022
Title **
[English]
COMPOUNDS TARGETING Y220C MUTANT OF P53
[French]
COMPOSÉS CIBLANT LE MUTANT Y220C DE P53
Applicants **
JACOBIO PHARMACEUTICALS CO., LTD.
Unit 2
Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area Daxing
Beijing 101111, CN
Inventors
LI, Sujing
Unit 2
Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area Daxing
Beijing 101111, CN
LI, Amin
Unit 2
Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area Daxing
Beijing 101111, CN
ZHENG, Qian
Unit 2
Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area Daxing
Beijing 101111, CN
DANG, Chaojie
Unit 2
Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area Daxing
Beijing 101111, CN
FAN, Xinrui
Unit 2
Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area Daxing
Beijing 101111, CN
LONG, Wei
Unit 2
Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area Daxing
Beijing 101111, CN
WANG, Yanping
Unit 2
Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area Daxing
Beijing 101111, CN
Priority Data
PCT/CN2021/085870
08.04.2021
CN
PCT/CN2021/089287
23.04.2021
CN
PCT/CN2021/137124
10.12.2021
CN
PCT/CN2021/089311
23.04.2021
CN
PCT/CN2021/089317
23.04.2021
CN
PCT/CN2021/136450
08.12.2021
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2828 | |
| EPO | Filing, Examination | 13201 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 738 | |
| USA | Filing, Examination | 5410 |
Total: 22768 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided are compounds of formula (I) which can bind to p53 mutant and restore its ability to bind DNA and activate downstream effects involved in tumor suppression. Also provided are the synthesis processes and use of the compounds.[French]
L'invention concerne des composés de formule (I) qui peuvent se lier au mutant de p53 et restaurer sa capacité à se lier à l'ADN et à activer les effets en aval impliqués dans la suppression tumorale. L'invention concerne également les procédés de synthèse et l'utilisation des composés.